| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 临床前研究(元) | 40,883,445.30 | 63,901,032.43 | 25,762,625.11 | 39,668,184.51 |
| 药物发现(元) | 143,398,784.85 | 200,029,007.69 | 81,557,704.16 | 155,360,217.93 |
| 营业成本(元) | ||||
| 临床前研究(元) | 25,578,034.80 | 43,760,291.37 | 19,211,847.14 | 36,207,952.69 |
| 药物发现(元) | 52,177,200.63 | 89,790,245.20 | 41,445,308.68 | 84,345,540.45 |
| 毛利(元) | ||||
| 临床前研究(元) | 15,305,410.50 | 20,140,741.06 | 6,550,777.97 | 3,460,231.82 |
| 药物发现(元) | 91,221,584.22 | 110,238,762.49 | 40,112,395.48 | 71,014,677.48 |
| 毛利率(%) | ||||
| 临床前研究(%) | 37.44 | 31.52 | 25.43 | 8.72 |
| 药物发现(%) | 63.61 | 55.11 | 49.18 | 45.71 |
| 收入构成(%) | ||||
| 临床前研究(%) | 22.19 | 24.21 | 24.01 | 20.34 |
| 药物发现(%) | 77.81 | 75.79 | 75.99 | 79.66 |
| 毛利构成(%) | ||||
| 临床前研究(%) | 14.37 | 15.45 | 14.04 | 4.65 |
| 药物发现(%) | 85.63 | 84.55 | 85.96 | 95.35 |